Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: Improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties

被引:69
作者
Nair, AC
Jayatilleke, P
Wang, X
Miertus, S
Welsh, WJ
机构
[1] Univ Missouri, Dept Chem & Biochem, St Louis, MO 63121 USA
[2] Univ Missouri, Ctr Mol Elect, St Louis, MO 63121 USA
[3] UNIDO, Int Ctr Sci & High Technol, I-34012 Trieste, Italy
关键词
D O I
10.1021/jm010417v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A computational chemistry study has been performed on a series of tetrahydropyrimidine-2-ones (THPs) as HIV-1 protease (HIV-1 PR) inhibitors. The present investigation focuses on the correlation of inhibitor-enzyme complexation energies (E-comp1), inhibitor solvation energies E-solv[I], and both polar and nonpolar buried surface areas (BSAs) with the observed values of the binding affinity (pK(I)). Various combinations of these specific inhibitor- and receptor-based properties were also evaluated as additional descriptors to three-dimensional quantitative structure-activity relationship (3D-QSAR) models constructed using comparative molecular field analysis (CoMFA). Linear regression of the observed pK(I) values with E-comp1,E-solv [I], the BSAs yielded a strong correlation in terms of both self-consistency (r(2) approximate to 0.90) and internal predictive ability (r(cv)(2) > 0.50). The 3D-QSAR models obtained from CoMFA using standard partial least-squares (PLS) analysis also yielded a strong correlation between the CoMFA fields and the experimental pK(i) (r(2) = 0.96; r(cv)(2) = 0.58). Various "enhanced" 3D-QSAR models were constructed in which different combinations of the E-comp1, Esolv[I], and BSAs were added as additional descriptors to the default steric-electrostatic CoMFA fields. Inclusion of E-solv[I] in particular yielded significant improvement in the predictive ability (r(cv)(2) approximate to 0.80) of the resultant 3D-QSAR model.
引用
收藏
页码:973 / 983
页数:11
相关论文
共 32 条
[1]   Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors [J].
Ala, PJ ;
Huston, EE ;
Klabe, RM ;
McCabe, DD ;
Duke, JL ;
Rizzo, CJ ;
Korant, BD ;
DeLoskey, RJ ;
Lam, PYS ;
Hodge, CN ;
Chang, CH .
BIOCHEMISTRY, 1997, 36 (07) :1573-1580
[2]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[3]   Resistance to human immunodeficiency virus type 1 protease inhibitors [J].
Boden, D ;
Markowitz, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2775-2783
[4]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[5]   CROSS-VALIDATION, BOOTSTRAPPING, AND PARTIAL LEAST-SQUARES COMPARED WITH MULTIPLE-REGRESSION IN CONVENTIONAL QSAR STUDIES [J].
CRAMER, RD ;
BUNCE, JD ;
PATTERSON, DE ;
FRANK, IE .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1988, 7 (01) :18-25
[6]   A DELETION MUTATION IN THE 5' PART OF THE POL GENE OF MOLONEY MURINE LEUKEMIA-VIRUS BLOCKS PROTEOLYTIC PROCESSING OF THE GAG AND POL POLYPROTEINS [J].
CRAWFORD, S ;
GOFF, SP .
JOURNAL OF VIROLOGY, 1985, 53 (03) :899-907
[7]   Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors [J].
De Lucca, GV ;
Liang, J ;
De Lucca, I .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (01) :135-152
[8]   Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors [J].
Debnath, AK .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1998, 38 (04) :761-767
[10]   Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors [J].
DeLucca, GV ;
Liang, J ;
Aldrich, PE ;
Calabrese, J ;
Cordova, B ;
Klabe, RM ;
Rayner, MM ;
Chang, CH .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (11) :1707-1719